Antidepressants – USA Today Editorial / AHRP OpEd/ WSJ Editorial Bashes Spitzer Mon, 21 Jun 2004 The debate about antidepressants, concealment of clinical trial data, and failure to warn about a suicide risk, is reaching an ever broader public. An editorial in USA Today and an invited Op Ed by…
NYS Attorney General files suit against GlaxoSmithKline for Concealing Drug Information Wed, 2 Jun 2004 The most positive development in the antidepressant drug saga is the filing of a much needed lawsuit by Eliot Spitzer, New York State Attorney General. The suit charges GlaxoSmithKline with having “engaged in repeated and…
Pfizer issues prosecutors a manual to defend drug – Star Ledger Thu, 5 Aug 2004 In the May 14, 2004, settlement of a lawsuit initiated by a whistleblower, Pfizer pleaded guilty to criminal fraud in the promotion of Neurontin, and agreed to pay $430 million. https://ahrp.org/infomail/04/05/16.php A report in The…
Tell the Truth About Antidepressants On Drug Labels & in Medical Journals Thu, 16 Sep 2004 An April, 2004 editorial in the New York Times noted: “What seems most astonishing is the skimpy evidence that these drugs work at all in most young patients.” What is astonishing is how the…
Unlawful drug marketing: GlaxoSmithKline & 4,000 doctors Face Criminal Charges in Italy Mon, 7 Jun 2004 On March 25, 2004, the US Attorney in Pennsylvania commenced an investigation of Eli Lilly’s marketing promotion of Zyprexa (olanzapine), Prozac (fluoxetine) and Evista (raloxifene). On April 19, a class action lawsuit was filed…
20% volunteers drop out after suicide in Eli Lilly’s duloxetine trial Thu, 12 Feb 2004 The Associated Press reports that nearly a fifth of the volunteers testing Eli Lilly’s antidepressant drug, duloxetine, dropped out after Traci Johnson, a 19-year old student committed suicide at a company laboratory. “Three participants in…
Failed Paxil drug tests in children concealed – Guardian UK Thu, 5 Feb 2004 The Guardian (UK) reports (below) that BBC Panorama had obtained secret 1998 documents from SmithKline Beecham (now GlaxoSmithKline, GSK) showing that the company deliberately concealed the failure of Seroxat / Paxil to demonstrate a benefit for…
AHRP Press Briefing Scientists Will Analyze SSRI Data – Families Will Tell Their Tragedies THE ALLIANCE FOR HUMAN RESEARCH PROTECTION (AHRP) 142 West End Ave. Suite 28P New York, NY 10023 January 27, 2004 Contact: Vera Hassner Sharav President, AHRP Tel. No: 212-595-8974 E-mail: Contact: Lisa Van Syckel Family Liaison…
Excerpt: The British drug authority has banned the use of most SSRI antidepressant drugs for the treatment of depression in children under 18, citing a two-to-threefold increased risk of suicidal behavior and lack of evidence of a benefit for depressed children. Two SSRIs – Paxil and Effexor – are no longer recommended by their manufacturer for use in children. Prozac is no longer recommended by Eli Lilly for children in the U.K.
In contrast to the British medicines authority review of the evidence, the FDA has refused to allow independent scientists to present documented evidence related to these drugs’ hazards and their failure to demonstrate a benefit for depressed children.
AHRP Correspondence with Government Agencies related link: FDA response to AHRP procedural questions (FDA sham conflicts of interest policy) FDA re: supression of SSRI evidence ALLIANCE FOR HUMAN RESEARCH PROTECTION (AHRP) 142 West End Ave, Suite 28P New York, NY 10023 https://ahrp.org Tel: 212-595-8974 e-mail: October 29, 2003 To: Thomas…
Prozac in Drinking Water / Prozac in Streams Hurt Frogs fish / Newborns suffer Withdrawal Tue, 10 Aug 2004 An article in the UK Observer–“Stay calm everyone, there’s Prozac in the drinking water” (below) — reports that British environmentalists are calling for an “urgent investigation into the revelations, describing the…
A growing Crisis: Aggressive Marketing of drugs for children_Lou Dobbs-CNN Fri, 3 Oct 2003 CNN’s anchor Lou Dobbs, an astute business journalist whose program Lou Dobbs Tonight on CNN examines politics, the economy and a broad range of issues that affect the quality of life and standard of living of…
